$3.08 Million in Sales Expected for Kala Pharmaceuticals Inc (NASDAQ:KALA) This Quarter

Equities research analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to announce $3.08 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Kala Pharmaceuticals’ earnings, with the highest sales estimate coming in at $4.27 million and the lowest estimate coming in at $2.50 million. The company is scheduled to announce its next earnings results on Monday, March 9th.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full year sales of $7.99 million for the current financial year, with estimates ranging from $7.40 million to $9.17 million. For the next fiscal year, analysts anticipate that the business will report sales of $29.61 million, with estimates ranging from $17.16 million to $46.39 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The company had revenue of $1.45 million during the quarter, compared to analyst estimates of $3.56 million.

Several equities analysts have recently commented on the company. Zacks Investment Research cut Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th. Wedbush reissued an “outperform” rating and set a $51.00 price target on shares of Kala Pharmaceuticals in a research report on Wednesday, August 7th. Oppenheimer set a $9.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target (down from $12.00) on shares of Kala Pharmaceuticals in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $17.85.

Large investors have recently bought and sold shares of the stock. Bank of Montreal Can grew its position in shares of Kala Pharmaceuticals by 148.5% in the 2nd quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock worth $26,000 after acquiring an additional 2,399 shares in the last quarter. Greenwich Wealth Management LLC lifted its stake in Kala Pharmaceuticals by 28.7% during the second quarter. Greenwich Wealth Management LLC now owns 13,000 shares of the company’s stock worth $83,000 after purchasing an additional 2,900 shares during the last quarter. Boston Partners boosted its holdings in Kala Pharmaceuticals by 4.7% in the third quarter. Boston Partners now owns 124,034 shares of the company’s stock worth $472,000 after purchasing an additional 5,603 shares during the period. Parametric Portfolio Associates LLC raised its holdings in shares of Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after purchasing an additional 5,806 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Kala Pharmaceuticals by 4.9% in the 2nd quarter. Northern Trust Corp now owns 198,260 shares of the company’s stock valued at $1,265,000 after buying an additional 9,183 shares during the period. Institutional investors and hedge funds own 64.21% of the company’s stock.

KALA stock traded down $0.12 during midday trading on Friday, hitting $4.02. 5,195 shares of the company’s stock were exchanged, compared to its average volume of 237,514. The company has a current ratio of 6.25, a quick ratio of 5.94 and a debt-to-equity ratio of 1.65. Kala Pharmaceuticals has a 12-month low of $3.24 and a 12-month high of $9.25. The firm has a 50 day moving average price of $3.81 and a 200-day moving average price of $4.74. The stock has a market capitalization of $144.72 million, a price-to-earnings ratio of -1.64 and a beta of 2.21.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: What is the S&P 500 Index?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.